Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40593518.
- Also identified by DOI 10.1038/s41467-025-60232-3 and PMC identifier 12217591.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase. Structural studies by single particle electron cryo-microscopy (cryo-EM) revealed that one of these single-domain antibodies prevents the conformational transition of the viral hemagglutinin to the post-fusion state by targeting a quaternary epitope spanning two protomers in the hemagglutinin-stem region. A second single-domain antibody broadly inhibits influenza B neuraminidase activity, including an oseltamivir-resistant neuraminidase, and its complex with neuraminidase elucidated by single particle cryo-EM established that it binds to residues in the neuraminidase catalytic site. Head-to-tail fusions of these single-domain antibodies led to bispecific binders that further improved the neutralization breadth and potency against influenza B viruses. These single-domain antibodies, fused to a human IgG1-Fc domain, fully protected female mice against an otherwise lethal influenza B virus challenge. Our findings underscore the potential of engineered single-domain antibodies to help control influenza B virus infections.
Medical subject headings
- Influenza B virus
- Single-Domain Antibodies
- Neuraminidase
- Antibodies, Viral
- Hemagglutinin Glycoproteins, Influenza Virus
- Orthomyxoviridae Infections
- Viral Proteins